Lab Models Built From Tumor Samples of People With Sarcoma or Cancer Spread
Uses leftover tumor samples from people with sarcoma or cancer spread to build lab models.
Plain-language title generated from the registry record
Registry title: Development of Innovative Preclinical Ex Vivo Models for the Study of Sarcomas and Metastases From Solid Tumors
Key facts
- Where
- Bologna, ItalySee the site
Where in Italy
- Istituto Ortopedico RizzoliBologna, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Istituto Ortopedico Rizzoli
- Trial code
- NCT07112989
- Record updated
- 8 August 2025
- Original description
The goal of this observational study is to learn how tumor tissue and blood samples from patients with sarcomas or metastases can be used to create laboratory models that help researchers study cancer behavior and test new treatments. Participants diagnosed with sarcoma or with bone or lung metastases from solid tumors will donate leftover tumor tissue and blood collected during their regular medical care. These samples will be used in the lab to build 3D models of the tumor, test drugs, and identify genetic and molecular markers. No treatments or procedures will be given as part of the study.Read full original descriptionShow less
Development of Innovative Preclinical Ex Vivo Models for the Study of Sarcomas and Metastases From Solid Tumors
The goal of this observational study is to learn how tumor tissue and blood samples from patients with sarcomas or metastases can be used to create laboratory models that help researchers study cancer behavior and test new treatments. Participants diagnosed with sarcoma or with bone or lung metastases from solid tumors will donate leftover tumor tissue and blood collected during their regular medical care. These samples will be used in the lab to build 3D models of the tumor, test drugs, and identify genetic and molecular markers. No treatments or procedures will be given as part of the study.
Inclusion: Patients (male or female) diagnosed with sarcoma or with bone or lung metastases from solid tumors; Age between 0 and 85 years; Availability of sufficient and adequate biological material (tumor tissue and/or blood); Signed informed consent for biobanking (BIOTUM); Signed informed consent for use of tissue and blood samples in this study.
Exclusion: Diagnosis other than sarcoma or metastases from solid tumors; Missing signed informed consent(s).